Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jul;6(3):118-21.
doi: 10.1177/1941874415591500. Epub 2015 Jun 19.

Heparin Resistance and Anticoagulation Failure in a Challenging Case of Cerebral Venous Sinus Thrombosis

Affiliations

Heparin Resistance and Anticoagulation Failure in a Challenging Case of Cerebral Venous Sinus Thrombosis

Adam B King et al. Neurohospitalist. 2016 Jul.

Erratum in

  • Corrigendum.
    [No authors listed] [No authors listed] Neurohospitalist. 2016 Oct;6(4):NP1. doi: 10.1177/1941874416669767. Epub 2016 Sep 19. Neurohospitalist. 2016. PMID: 27688823 Free PMC article.

Abstract

We report a challenging case of cerebral venous sinus thrombosis (multiple etiologic factors) that was complicated by heparin resistance secondary to suspected antithrombin III (ATIII) deficiency. A 20-year-old female previously healthy and currently 8 weeks pregnant presented with worsening headaches, nausea, and decreasing Glasgow Coma Scale/Score (GCS), necessitating mechanical ventilatory support. Imaging showed extensive clots in multiple cerebral venous sinuses including the superior sagittal sinus, transverse, sigmoid, jugular veins, and the straight sinus. She was started on systemic anticoagulation and underwent mechanical clot removal and catheter-directed endovascular thrombolysis with limited success. Complicating the intensive care unit care was the development of heparin resistance, with an inability to reach the target partial thomboplastin time (PTT) of 60 to 80 seconds. At her peak heparin dose, she was receiving >35 000 units/24 h, and her PTT was subtherapeutic at <50 seconds. Deficiency of ATIII was suspected as a possible etiology of her heparin resistance. Fresh frozen plasma was administered for ATIII level repletion. Given her high thrombogenic risk and challenges with conventional anticoagulation regimens, we transitioned to argatroban for systemic anticoagulation. Heparin produces its major anticoagulant effect by inactivating thrombin and factor X through an AT-dependent mechanism. For inhibition of thrombin, heparin must bind to both the coagulation enzyme and the AT. A deficiency of AT leads to a hypercoagulable state and decreased efficacy of heparin that places patients at high risk of thromboembolism. Heparin resistance, especially in the setting of critical illness, should raise the index of suspicion for AT deficiency. Argatroban is an alternate agent for systemic anticoagulation in the setting of heparin resistance.

Keywords: cerebrovascular disorders; clinical specialty; hematology; neurocritical care; stroke.

PubMed Disclaimer

Conflict of interest statement

Declaration of Conflicting Interests: The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
Magnetic resonance venography (MRV) of the brain showing extensive cerebral venous sinus thrombosis (CVST) involving the numbered structures: (1) sigmoid sinus, (2) transverse sinus, (3) straight sinus, and (4) superior sagittal sinus.
Figure 2.
Figure 2.
Magnetic resonance imaging (MRI) of the brain (gradient echo sequence) showing thrombosis of occipital portion of the superior sagittal sinus and extensive thrombosis of the cortical veins.
Figure 3.
Figure 3.
Multiplanar multisequence Magnetic resonance imaging without intravenous contrast. MRV was completed using 3-dimensional (3D) phase-contrast technique without IV contrast. Scan showing extensive cerebral venous sinus thrombosis (CVST) and new infarcts in the basal ganglia and corpus callosum.

Similar articles

Cited by

References

    1. Bousser MG, Ferro JM. Cerebral venous thrombosis: an update. Lancet Neurol. 2007;6(2):162–170. - PubMed
    1. Coutinho J, de Bruijn SF, Deveber G, Stam J. Anticoagulation for cerebral venous sinus thrombosis. Cochrane Database Syst Rev. 2011;(8):CD002005. - PMC - PubMed
    1. Saadatnia M, Fatehi F, Basiri K, Mousavi SA, Mehr GK. Cerebral venous sinus thrombosis risk factors. Int J Stroke. 2009;4(2):111–123. - PubMed
    1. Dentali F, Squizzato A, Gianni M, et al. Safety of thrombolysis in cerebral venous thrombosis. A systematic review of the literature. Thromb Haemost. 2010;104(5):1055–1062. - PubMed
    1. Hirsh J, Bauer KA, Donati MB, et al. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 suppl):141S–159S. - PubMed

LinkOut - more resources